Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2024)
41 slides from Noxopharm's shareholder meeting presentation, Nov 19, 2024
Slide 1: Noxopharm 2024 AGM Corporate Presentation
Noxopharm 2024 AGM Corporate Presentation Sydney, 19 November 2024: Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to release its 2024 AGM Corporate Presentation. Highlights: • Ongoing strategic transformation • Two proprietary technology platforms with multiple assets • Numerous
Slide 2: Forward Looking Statements
“estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and even
Slide 3: Noxopharm Limited – Delivering Science. Transforming Lives.
NOXOPHARM LIMITED Delivering Science. Transforming Lives. AGM 2024 NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be
Slide 5: Noxopharm AGM Presentation
Noxopharm Dr Gisela Mautner, CEO & MD AGM Presentation 19 November 2024
Slide 6: Transforming Noxopharm
Transforming Noxopharm • Two proprietary technology platforms • Multiple high-potential assets • Growing external interest in Sofra platform • Clinical trial starting in 2025 • Encouraging results from Chroma platform • World-class partners • Robust IP portfolio • Highly experienced management team
Slide 7: The Noxopharm Business Model
The Noxopharm Business Model Proprietary and in-licensed drugs are advanced through Out-licensing drug development, with a Upfront payment Milestones view to out-licensing them Royalties at key value inflection points. Clinical Pre-Clinical Out-licensing Upfront payment Milestones Own & Royalties In
Slide 8: Financial Summary (ASX:NOX)
Financial Summary (ASX:NOX) Funding from sophisticated investors announced September 2024 Capital Structure* Cash Position** Share price $0.105 Current Cash Holdings $1.6M Shares on issue 292M R&D rebate received for 2023/24 $2.4M Market Capitalisation $30.7M Net capital raised1 $63.8M Govt grants/r
Slide 9: Two Separate Development Programs
Two Separate Development Programs 7
Slide 10: Noxopharm Chroma
Noxopharm Chroma™
Slide 11: Chroma Tech Platform
Cancer ha Pancreatic Cancer JS \ CHROMA™ TECH PLATFORM Brain Cancer Leukaemia Inflammation
Slide 12: Pancreatic Cancer Dual-Cell Therapy
Pancreatic Cancer Dual-Cell Therapy • Preclinical research in unique pancreatic cancer UNSW model • CRO-67 tested in patient-derived explants • CRO-67 attacks both pancreatic tumour cells and barrier cells surrounding the tumour • Reducing the barrier exposes tumour to immune cells and to further an
Slide 13: Significant in vivo Results August 2024
Significant in vivo Results August 2024 Significant Decrease in Tumour Volume Growth • New results from highly sophisticated study Rate testing CRO-67 in complex model • Human pancreatic cancer cells as well as barrier cells were transplanted into the pancreas of mice • The study had three major res
Slide 14: Chroma Tech Platform
Cancer Inflammation CHROMA™ TECH PLATFORM Pancreatic Cancer Brain Cancer JS \ Leukaemia NOXOPHARM
Slide 15: Glioblastoma
Glioblastoma • Noxopharm and the University of South Australia (UniSA) have identified two novel first-in-class drugs with anticancer activity – CRO-70 and CRO-71. • Drugs tested on an extensive biobank of patient-derived tumour explant organoids (GBOs); a state-of-the-art glioblastoma explant model
Slide 16: Chroma Tech Platform
Cancer Inflammation CHROMA™ TECH PLATFORM Pancreatic Cancer Brain Cancer Leukaemia NOXOPHARM
Slide 17: Leukaemia
Leukaemia • Novel drug identified that specifically targets a gene mutation found in Acute Myeloid Leukaemia (AML) that arises during current standard-of-care treatment. • Mutation causes the cancer to become resistant to standard-of-care drugs. • Early findings show the novel Chroma drug candidate
Slide 18: Noxopharm Sofra
Noxopharm Sofra™
Slide 19: RNA Revolution
RNA Revolution • RNA technology represents a revolution in medicine. • The third wave of drug history is starting: from small molecules to monoclonal antibodies to RNA. Small molecules Monoclonal antibodies RNA 17
Slide 20: Noxopharm and the RNA Revolution
Noxopharm and the RNA Revolution • The COVID vaccines were just the beginning. • RNA technology will see new medicines and vaccines launched in unprecedented numbers over the coming years. • Noxopharm is one of very few Australian companies in the RNA space. • We have proprietary technology to 1. Cr
Slide 21: Scientific Breakthrough
Scientific Breakthrough • The 2023 Nobel Prize for Medicine was awarded to Katalin Karikó and Drew Weissman. • They paved the way for mRNA COVID vaccines by discovering how mRNA interacts with our immune system. • They used nucleoside base modifications to reduce inflammation by replacing one base c
Slide 22: Licensing Deals – COVID-19 Vaccines
Licensing Deals – COVID-19 Vaccines • Cellscript licensed modified uridine technology from the University of Pennsylvania after it was discovered there by Karikó and Weissman. • Cellscript later licensed it to the BioNTech/Pfizer team and Moderna. • The exact amount Cellscript made from licensing mo
Slide 23: Growing Markets for RNA Medicines
Growing Markets for RNA Medicines • RNA medicines will represent a very sizeable market in the coming years. • The mRNA market alone was already US$40 billion in 2022. • It is expected to grow to US$137 billion by 2032 at a compound annual growth rate of 13%. • COVID-19 vaccines will soon represent
Slide 24: Further Nobel Prize recognition
Further Nobel Prize recognition • The 2024 Nobel Prize for Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. • Groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be
Slide 25: Sofra
Sofra • Noxopharm has in-licensed a technology from Hudson Institute of Medical Research to create the Sofra technology platform. • This technology platform is based upon short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. • These oligonucleotides provide a no
Slide 26: Sofra Tech Platform
Stimulate Inflammatory Response Infectious Inflammatory Diseases Cancer Cardiovascular Diseases ) _ J® . NOXOPHARM : SOFRA™ TECH PLATFORM 4 a, mRNA \ J Oligonucleotides targeting inflammatory sensors Weeds Other therapeutics Neurodegenerative Diseases Parkinson's Alzheimer's Huntington's Multiple Sc
Slide 27: SOF-SKN – Overview
SOF-SKN – Overview • Skin diseases are distressing to patients, especially when they visibly affect the face and limbs. • Current treatments are insufficient – corticosteroids are commonly used but have severe side effects. • To help patients and capitalise on a major market opportunity, we are deve
Slide 28: SOF-SKN Mechanism of Action
SOF-SKN Mechanism of Action 26
Slide 29: The HERACLES Clinical Trial
The HERACLES Clinical Trial • First-in-human trial for SOF-SKN aims to provide initial data from healthy volunteers. • Ultimate goal to target the skin disease caused by cutaneous lupus erythematosus (CLE). • HERACLES (for ‘Harnessing Endogenous Regulators Against CLE Study’), will take place in Aus
Slide 30: Sofra Tech Platform
Stimulate Inflammatory Response Infectious Inflammatory Diseases SOFRA™ TECH PLATFORM Oligonucleotides targeting inflammatory sensors Cancer Neurodegenerative Diseases + Parkinson's + Alzheimer's + Huntington's + Multiple Sclerosis Cardiovascular Diseases — -» + Hypertension: NOXOPHARM : purges Pulm
Slide 31: SOF-VAC – Mechanism of Action
SOF-VAC – Mechanism of Action • SOF-VAC has been specifically developed to reduce mRNA vaccine reactogenicity. • SOF-VAC is designed to be co-delivered with mRNA to selectively block TLR7/8. • By blocking these inflammation receptors, SOF-VAC reduces vaccine side effects. 29
Slide 32: SOF-VAC – Benefits
SOF-VAC – Benefits The ability of SOF-VAC to reduce the inflammatory side effects of mRNA vaccines or drugs has several potential benefits, such as: • Enabling mRNA vaccines to be given with higher doses – creating longer- lasting protection and a decrease in the frequency of booster shots required.
Slide 33: Sofra Tech Platform
Stimulate Inflammatory Response Infectious Inflammatory Diseases Cancer _ NOXOPHARM SOFRA™ TECH PLATFORM Oligonucleotides targeting inflammatory sensors Neurodegenerative Diseases + Parkinson's + Alzheimer's + Huntington's + Multiple Sclerosis Cardiovascular Diseases + Hypertension + Atherosclerosis
Slide 34: Sofra and Cancer
Sofra and Cancer Noxopharm has developed drug candidates that can increase the potency of TLR8 inflammation sensors. • TLR8 plays an important role in the innate immune system • Sofra could therefore be used in immuno-oncology, to help stimulate the immune system in the fight against cancer • Decisi
Slide 35: Robust Sofra IP
Robust Sofra IP • Noxopharm is building a robust patent portfolio that protects its valuable intellectual property across strategic global markets. • Hundreds of assets covered with potential to treat a wide variety of diseases. • PCT applications filed in all major jurisdictions. • Pending composit
Slide 36: Sofra Commercialisation
Sofra Commercialisation • Range of mid-size to multibillion-dollar companies now evaluating Sofra assets. • Company names have to remain confidential in highly competitive market. • Several Material Transfer Agreements (MTAs) signed over past few months. • An MTA governs the transfer of materials be
Slide 37: Sofra – Potential Partner Types
Sofra – Potential Partner Types RNA therapeutics RNA vaccine developers developers SOFRA PLATFORM Conjugated drug companies – linking Drug delivery drugs to other technology molecules for companies looking for highly targeted payloads delivery 35
Slide 38: Sofra – Potential Partners – Signed MTAs
Sofra – Potential Partners – Signed MTAs RNA therapeutics RNA vaccine developers developers SOFRA PLATFORM Conjugated drug companies – linking Drug delivery drugs to other technology molecules for companies looking for highly targeted payloads delivery 36
Slide 39: Noxopharm – Next Steps
Noxopharm – Next Steps • Continue preparations for HERACLES clinical trial • Select contract research organisation and Phase 1 unit • Finalise preclinical studies • Support ongoing MTAs, target additional ones • Further strengthen relationship with Hudson Institute of Medical Research • Promote awar
Slide 40: Pipeline
Pipeline Program Discovery Screening Preclinical Clinical Collaborators CRO-67 Pancreatic Cancer UNSW Sydney CRO-70&71 Brain Cancer Uni SA Chroma Undisclosed Blood Cancer Uni SA Hudson Institute of SOF-VAC Adjuvant for mRNA vaccines/drugs Medical Research Hudson Institute of SOF-SKN Autoimmune skin
Slide 41: Noxopharm Questions
Noxopharm Questions